On September 11, CHINA LIFE fell 3.05% in regular trading, trading at 29.22 HKD/share, with turnover of 167 million HKD. The broader insurance sector weakened in tandem, with Ping An down 2.55%, NCI down 2.57%, and China Taiping down 2.32%.

The decline reflects ongoing market digestion of the Ministry of Finance's September 6 announcement to inject 350 billion yuan into China Life Group — the single largest allocation among the five state-owned insurers that collectively received 700 billion yuan. The injection targets the group level rather than the listed entity directly, with brokerages noting that near-term financial metrics of the listed subsidiary will not be directly diluted. However, sector sentiment remains under repeated pressure during the post-announcement adjustment period.

Fundamentally, CHINA LIFE reported robust first-half results with net profit attributable to shareholders surging 228.6% year-over-year to 134.489 billion yuan, and proposed an interim dividend of 0.358 yuan per share totaling approximately 10.119 billion yuan, up 50.4% year-over-year. JPMorgan has recommended buying on weakness, citing an attractive valuation of roughly 5x forward P/E and a 4% dividend yield.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)